Use of Somatropin in Turner Syndrome

The Use of Norditropin® in Turner's Syndrome

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01518036

Enrollment

Registered

2012-01-25

Start date

1987-09-14

Completion date

2004-04-11

Last updated

2017-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Disorder, Turner Syndrome

Brief summary

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

Interventions

DRUGsomatropin

2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

2 Years to 11 Years

Healthy volunteers

Inclusion criteria

* Turner Syndrome * Not previously treated with growth hormone or androgen * Well-documented height over the previous 12 months * Informed consent of parents (and child if appropriate)

Exclusion criteria

* Growth hormone (GH) deficiency based on a GH stimulation test

Design outcomes

Primary

Measure	Time frame
Final height in cm	—

Secondary

Measure	Time frame
Ratio between change in bone age and change in chronological age	—
Age at onset of puberty	—
Adverse events	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026